Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Allergan purchasing Kythera Biopharmaceuticals for $2.1 billion

By Pharmaceutical Processing | June 18, 2015

In recent news, Allergan will be purchasing Kythera Biopharmaceuticals for $2.1 billion. With this purchase, Allergan will also be acquiring KYBELLA, a submental fat therapy injection. A leading expert from Frost & Sullivan’s Healthcare & Life Sciences, Barbara Gilmore, comments below on the topic.

According to senior industry analyst Barbara Gilmore:

“Allergan is firing on all cylinders.  Allergan, the company behind Botox, acquired Kythera, a small specialty biotech company focused on the development of high-value prescription drugs for the aesthetic market, for $2.1B.” 

“Kythera’s ATX-101, a non-surgical injectable for the treatment of adults with moderate-to-severe submental fat below the chin, was approved by the FDA on April 29, 2015.  ATX-101 is the first and only FDA-approved drug for submental contouring, in an aesthetic injectable market estimated to be worth $1.7B by 2017.” 

“Both dermatology and aesthetic medicine are key areas of focus for Allergan, so the fit is natural for both companies.  Kythera brings a leadership team with experience in the strategic commercialization of Botox Cosmetic, JUVEDERM and Latisse.  While Allergan’s strategy is successful at a time when most major pharmaceutical companies are scrambling to recover from patent cliff income collapse.  Allergan has invested in a small niche markets while maintaining a strong broad patent portfolio on its products.”

Related Articles Read More >

Sandoz Logo 2025
Sandoz breaks ground on biosimilar plant in Slovenia
Nymi Logo_2022 (1)
Nymi, Caliber partner on passwordless authentication for pharma manufacturing
Building a resilient pharma supply chain
Antheia_Logo (1)
Pharma ingredient manufacturer Antheia raises $56M Series C
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE